Fig. 4
Prevalence of seroconversion after the third dose in CAR-T cell therapy recipients, which is significantly lower than in the HSCT group
Fig. 4 | Virology Journal
Prevalence of seroconversion after the third dose in CAR-T cell therapy recipients, which is significantly lower than in the HSCT group
Virology Journal